Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer

  • Agenus Inc AGEN presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021.
  • Related: Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer.
  • The Phase 2 trial evaluated the combination of Balstilimab and zalifrelimab in patients with recurrent/metastatic (R/M) cervical cancer (CC).
  • In the 125 evaluable patients, the overall objective response rate (ORR) was 26%, with 9% of patients achieving a complete response and 17% of patients achieving a partial response. 
  • The median duration of response (DoR) was not reached after a 19.4-month median follow-up. 
  • Notably, responses were observed in the PD-L1 negative and adenocarcinoma populations, with 9% of both patient groups achieving an ORR. 
  • Based on these observations, the Company predicts that more than half of the patients will be alive beyond 12 months.
  • The Bal/Zal combination continued to show no unexpected toxicities, and no new safety signals were identified.
  • Furthermore, later in 2021, Agenus expects to present new data on next-generation CTLA-4 inhibitor AGEN1181.
  • Price Action: AGEN stock is up 4.85% at $5.84 during the premarket session on the last check Friday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCervical CancerESMO21Phase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!